Crinetics Pharmaceuticals to be Acquired by Vertex for $10 Billion in Cash
CRNX has more than doubled off its 52-week low of $25.83 on elevated volume (4.2× avg).
Summary
Crinetics Pharmaceuticals has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, a deal valued at $10.0 billion, bringing its commercial and pipeline assets into a larger biotech company.
Key Events · M&A and Partnerships · CRNX
-
Acquisition Agreement
Vertex Pharmaceuticals will acquire Crinetics for $85.00 per share in cash.
-
Transaction Value
The deal is valued at approximately $10.0 billion in equity, or $8.8 billion net of estimated cash acquired.
-
Strategic Rationale
The acquisition integrates Crinetics' commercialized drug PALSONIFY and its Phase 3 candidate Atumelnant, which are expected to contribute over $5 billion in combined annual revenue at peak.
-
Financing Details
Vertex plans to finance the acquisition using a combination of cash on hand and $4.5 billion in committed bridge financing.
Analysis · CRNX · Life Sciences
Vertex Pharmaceuticals will acquire Crinetics for $85.00 per share in cash, representing a significant premium over the current market price. This definitive merger agreement, valued at approximately $10.0 billion, will integrate Crinetics' commercialized acromegaly drug PALSONIFY and its Phase 3 CAH candidate Atumelnant into Vertex's portfolio, accelerating revenue growth and enhancing long-term earnings. The deal is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
At the time of this filing, CRNX was trading at $84.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.83 to $57.99. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.